The estimated Net Worth of Eric J Ende is at least 594 千$ dollars as of 18 May 2023. Eric Ende owns over 13,000 units of Matinas Biopharma Inc stock worth over 593,527$ and over the last 8 years he sold MTNB stock worth over 0$. In addition, he makes 0$ as Independent Director at Matinas Biopharma Inc.
Sign up
Eric Ende MTNB stock SEC Form 4 insiders trading
Eric has made over 11 trades of the Matinas Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 13,000 units of MTNB stock worth 181,090$ on 18 May 2023.
The largest trade he's ever made was buying 35,000 units of Matinas Biopharma Inc stock on 31 May 2022 worth over 78,050$. On average, Eric trades about 4,615 units every 35 days since 2017. As of 18 May 2023 he still owns at least 167,900 units of Matinas Biopharma Inc stock.
You can see the complete history of Eric Ende stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Ende biography
Dr. Eric J. Ende M.D. serves as Independent Director of the Company. Since 2009, has served on our board of directors since April 2017. Dr. Ende is president of Ende BioMedical Consulting Group, a privately-held consulting company which is focused on helping life sciences companies raise capital, identify licensing partners, and optimize corporate structure as well as analyzing both private and public investment opportunities for clients within the life sciences industry, a position he has held since 2009. Dr. Ende serves as co-founder, chief executive and chief financial officer of WellFit Holdings, LLC, a private company focused on developing fitness technologies. In addition, Dr. Ende consulted with Icahn Enterprises in their efforts to appoint board members at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende served on the board of directors and as a member of the audit and risk management committee of Genzyme Corp. (NASDAQ: GENZ) from 2010 until it was acquired by Sanofi (NSYE: SNY) in 2011. Dr. Ende is currently serving on the Technology Transfer Committee of Mount Sinai Innovation Partners and served as the Chairman of the Unsecured Creditor’s Committee overseeing the bankruptcy of Egenix, Inc. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 through 2002, Dr. Ende was the senior biotechnology analyst at Banc of America Securities and, from 1997 to 2000, he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990. Ende is qualified to serve on our board of directors due to his industry experience, including as president of Ende BioMedical Consulting Group and as a biotechnology analyst, and his prior public company board experience.
How old is Eric Ende?
Eric Ende is 51, he's been the Independent Director of Matinas Biopharma Inc since 2017. There are 12 older and 3 younger executives at Matinas Biopharma Inc. The oldest executive at Matinas Biopharma Holdings Inc is Herbert Conrad, 87, who is the Independent Chairman of the Board.
What's Eric Ende's mailing address?
Eric's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Insiders trading at Matinas Biopharma Inc
Over the last 8 years, insiders at Matinas Biopharma Inc have traded over 0$ worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth 1,139,222$ . The most active insiders traders include Patrick G Lepore、Adam K Stern、James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of 187,938$. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth 16,600$.
What does Matinas Biopharma Inc do?
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
What does Matinas Biopharma Inc's logo look like?
Complete history of Eric Ende stock trades at Avadel Pharmaceuticals plc、Progenics Pharmaceuticals、Matinas Biopharma Inc、NeuBase Therapeutics
Matinas Biopharma Inc executives and stock owners
Matinas Biopharma Inc executives and other stock owners filed with the SEC include:
-
Jerome Jabbour,
President, Chief Executive Officer, Director -
Keith Kucinski,
Chief Financial Officer -
James Ferguson,
Chief Medical Officer -
Jerome D. Jabbour J.D.,
Co-Founder, CEO, Pres & Director -
Theresa Matkovits,
Chief Development Officer -
Dr. James J. Ferguson FACC, M.D.,
Chief Medical Officer -
Dr. Theresa Matkovits Ph.D.,
Chief Devel. Officer -
Raphael Mannino,
Chief Scientific Officer -
Ian Cooney,
Director ,Investor Relations & Corporate Development -
Matthew Wikler,
Independent Director -
James Scibetta,
Independent Director -
Natasha Giordano,
Independent Director -
Eric Ende,
Independent Director -
Patrick LePore,
Independent Vice Chairman of the board -
Herbert Conrad,
Independent Chairman of the Board -
Thomas J. Hoover M.B.A.,
Chief Bus. Officer -
Frank Calamusa,
Exec. Director and Head of Manufacturing & Supply Chain -
Dr. Raphael J. Mannino Ph.D.,
Chief Scientific Officer -
Dr. Hui Liu M.B.A., Ph.D.,
Chief Technology Officer -
Keith A. Kucinski CPA, M.B.A.,
Chief Financial Officer -
Adam K Stern,
Director -
Dominick Di Paolo,
Senior VP of Compliance -
Gary Gaglione,
Chief Financial Officer -
Roelof Rongen,
Chief Executive Officer -
Jennifer Gjg Life Sciences,...,
-
Stefano Ferrari,
Director -
Hui Liu,
Chief Technology Officer -
Kathryn Penkus Corzo,
Director -
Thomas Hoover,
Chief Business Officer